Amylin Pharmaceuticals Inc.

Amylin Pharmaceuticals Inc.

Product: AC137 amylin analog

Indication: Type 1 juvenile onset diabetes

Phase II data presented at the American Diabetes Association showed that at 14 days, the 21 patients in the placebo group had post-meal glucose (mean of changes in AUC) of +229.

The 15 patients in the 30 µg group had post-meal glucose of

-6,645 mg/dl (p=0.02) and tripro-amylin plasma peaks of

Read the full 680 word article

How to gain access

Continue reading with a
two-week free trial.